Skip to main content
. 2021 Jul;32(7):1616–1629. doi: 10.1681/ASN.2020071029

Figure 5.

Figure 5.

Treatment with empagliflozin (EMPA) prevents the reduction in GFR and attenuates proteinuria in HF rats. Rats were individually placed into metabolic cages for 24-hour urine collection to measure GFR and proteinuria. Blood was collected for the determination of serum urea and creatinine. (A) The GFR was estimated by creatinine clearance and normalized per gram of kidney weight (KW). (B) Serum urea was measured by colorimetry. (C) Graphic representation of the urine protein-creatinine ratio. Proteinuria was measured by colorimetry. Experiments were conducted 4 weeks after treatment with EMPA or no treatment. The values represent individual measurements and the means ± SEM. **P=0.001 versus sham; ***P<0.001 versus sham; ††† P<0.001 versus sham + EMPA; ## P=0.001 versus HF; ### P<0.001 versus HF.